Top 20 Biopharma M&A of 2023 by Total Deal Value

Shots: With stringent antitrust regulation clasping the overall volume of M&A deals, the biopharma industry manages to hold up a few strong M&A while conquering the waves of unexpected economic turmoil in 2023 In 2023, the global biopharma industry witnessed an astounding transformation with M&A deals. Pfizer’s acquisition of Seagen for $43B ranks first in…

ByPrince GiriJanuary 24, 2024

INSIGHTS+

Insights+: The US FDA New Drug Approvals in November 2023

Shots: The US FDA approved 5 NDAs & 4 BLAs in November 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 109 novel products in 2023 In November 2023, the major highlights drugs were Wezlana (ustekinumab) approved for Multiple Inflammatory Diseases, and Cosentyx (secukinumab) for the Treatment…

BySenior EditorDecember 20, 2023

VIEWPOINTS

Paul Moss Shares Insights from RWE Inform Study from AstraZeneca at IDWeek 2023

Shots: Paul Moss Professor of Hematology and Deputy Head of the College of Medicine at the University of Birmingham, shares insights from the RWE INFORM study from AstraZeneca INFORM used record data from 12 million people in the UK to study the relative risk of severe COVID-19 infection in patients with immune suppression Even though…

BySaurabh ChaubeyDecember 18, 2023

VIEWPOINTS

Helen Yeh & Naim Shehadeh in a Stirring Conversation with PharmaShots, Highlight the Results from T2NOW Study

Shots: At the EASD, AZ announced positive results from the T2NOW P-III study that evaluated the efficacy and safety of Forxiga as an add-on treatment in children and adolescents with T2D receiving metformin, insulin, or both Helen Yeh, VP, CVRM Therapy Area Biopharmaceuticals Medical at AstraZeneca, and Naim Shehadeh, Professor of Endocrinology, Rambam Health Care…

BySaurabh ChaubeyDecember 11, 2023

VIEWPOINTS

Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

Shots While sharing the details on Fasenra, Andrew highlights the unmet medical need in the healthcare sector as there’s only one approved treatment for EGPA With mepolizumab as the comparator drug for the trial, Andrew shares the positive results in achieving remission rates. Andrew sheds light on the unique mechanism of benralizumab that directly targets…

BySaurabh ChaubeyDecember 4, 2023

INSIGHTS+

Top Performing Drug – Tagrisso (October Edition)

Shots: In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Tagrisso and prepared a curated analysis report for our readers Tagrisso is indicated for the treatment of non-small-cell lung carcinomas with specific mutations. It is a 3rd generation drug that belongs to the…

BySenior EditorOctober 25, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2023

Shots: Third quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, Biogen acquired Reata Pharmaceuticals for ~$7.3B and Danaher acquired Abcam for ~$5.7B The third quarter of the year also showcases multiple clinical trial results which include Janssen reported P-IIb…

BySenior EditorOctober 2, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in July 2023

Shots: The EMA approved 9 New Chemical Entity (NCE) and 5 Biologic Drugs in July 2023, leading to treatments for patients and advances in the healthcare industry In July 2023, the major highlights drugs were Soliris approval for refractory generalised myasthenia gravis and Trodelvy for pre-treated HR+/HER2- metastatic breast cancer PharmaShots has compiled a list…

BySenior EditorAugust 24, 2023

TOP 20

Top 20 Companies Spending on R&D in 2022

Shots: R&D (Research and Development) in the biopharma industry lays the foundation stone of innovative drugs. A robust R&D bolstered with new-age technological advances assures long-term sustainability in the future market With a global expenditure of $238B in 2022, the figures are anticipated to reach $285B by 2028. In 2022, AbbVie ranked the top among…

ByPrince GiriAugust 22, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in July 2023

Shots: The US FDA approved 5 NDAs and 2 BLA in July 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 76 novel products in 2023 In July 2023, the major highlights drugs were Beyfortus (nirsevimab) approval for the prevention of RSV lower respiratory tract disease in…

BySenior EditorAugust 16, 2023

Top 20 Biopharma M&A of 2023 by Total Deal Value

Insights+: The US FDA New Drug Approvals in November 2023

Paul Moss Shares Insights from RWE Inform Study from AstraZeneca at IDWeek 2023

Helen Yeh & Naim Shehadeh in a Stirring Conversation with PharmaShots, Highlight the Results from T2NOW Study

Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

Top Performing Drug – Tagrisso (October Edition)

PharmaShots’ Key Highlights of Third Quarter 2023

Insights+: EMA Marketing Authorization of New Drugs in July 2023

Top 20 Companies Spending on R&D in 2022

Insights+: The US FDA New Drug Approvals in July 2023

Contact US

FOLLOW US